Skip to main content

Table 5 Supporting agents used in treatment

From: COVID-19 pandemic crisis—a complete outline of SARS-CoV-2

Antiviral agents

Supporting agents

Others

• Baloxavir

• Chloroquine phosphate

• Favipiravir

• HIV protease inhibitors

• Hydroxychloroquine

• Neuraminidase inhibitor

• Remdesivir

• Umifenovir

• Anakinra

• Azithromycin

• Baricitinib (Olumiant®)

• Colchicine

• Corticosteroids (general)

• COVID-19

• Convalescent plasma

• Epoprostenol (inhaled)

• Methylprednisolone (DEPO-Medrol®, SOLU-Medrol®)

• Nitric oxide (inhaled)

• Ruxolitinib (Jakafi®)

• Sarilumab (Kefzara®)

• Siltuximab (Sylvant®)

• Sirolimus (Rapamune®)

• Tocilizumab (Actemra®)

• ACE inhibitors, angiotensin II receptor blockers (ARBs)

• Anticoagulants (low molecular weight heparin [LMWH], unfractionated heparin [UFH])

• Famotidine

• HMG-CoA reductase inhibitors (statins)

• Immune globulin (IGIV, IVIG, γ-globulin)

• Ivermectin

• Nebulized drugs

• Niclosamide

• Nitazoxanide

• Nonsteroidal anti-inflammatory agents (NSAIDs)

• Tissue plasminogen activator (t-PA; alteplase)

  1. The repurposing of available therapeutic drugs is being used as supporting agents in the treatment of COVID-19; however, the efficacy of these treatments should be verified by using designed clinical trials